Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides
- PMID: 18399648
- DOI: 10.1021/jm701537z
Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides
Abstract
A number of 2'- O-modified antisense oligonucleotides have been reported for their potential use in oligonucleotide-based therapeutics. To date, most of the in vivo data has been generated for 2'-O-MOE (2'-O-methoxyethyl)- and 2'-O-Me (2'-O-methyl)-modified ASOs (antisense oligonucleotides). We now report the synthesis and biological activity of another 2'-O-modification, namely 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA). This modification resulted in an increase in the affinity of antisense oligonucleotides to complementary RNA similar to 2'-O-MOE-modified ASOs as compared to first-generation antisense oligodeoxynucleotides. The ASO modified with 2'-O-NMA reduced expression of PTEN mRNA in vitro and in vivo in a dose-dependent manner similar to 2'-O-MOE modified ASO. Importantly, toxicity parameters such as AST, ALT, organ weights, and body weights were found to be normal similar to 2'-O-MOE ASO-treated animal models. The data generated in these experiments suggest that 2'-O-NMA is a useful modification for potential application in both antisense and other oligonucleotide-based drug discovery efforts.
Similar articles
-
Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models.J Med Chem. 2010 Feb 25;53(4):1636-50. doi: 10.1021/jm9013295. J Med Chem. 2010. PMID: 20108935
-
Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.J Med Chem. 2009 Jan 8;52(1):10-3. doi: 10.1021/jm801294h. J Med Chem. 2009. PMID: 19086780
-
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides _targeting apolipoprotein B-100.Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14. Biochem Pharmacol. 2009. PMID: 19056355
-
Development of antisense oligodeoxynucleotides for transplantation.Curr Opin Mol Ther. 2000 Jun;2(3):304-17. Curr Opin Mol Ther. 2000. PMID: 11249625 Review.
-
An overview of sugar-modified oligonucleotides for antisense therapeutics.Chem Biodivers. 2011 Sep;8(9):1616-41. doi: 10.1002/cbdv.201100081. Chem Biodivers. 2011. PMID: 21922654 Review.
Cited by
-
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.Molecules. 2024 Oct 7;29(19):4737. doi: 10.3390/molecules29194737. Molecules. 2024. PMID: 39407665 Free PMC article. Review.
-
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.Acta Pharmacol Sin. 2024 Aug;45(8):1701-1714. doi: 10.1038/s41401-024-01261-4. Epub 2024 Apr 12. Acta Pharmacol Sin. 2024. PMID: 38609562
-
Antisense oligonucleotide is a promising intervention for liver diseases.Front Pharmacol. 2022 Dec 9;13:1061842. doi: 10.3389/fphar.2022.1061842. eCollection 2022. Front Pharmacol. 2022. PMID: 36569303 Free PMC article. Review.
-
Nonviral delivery systems for antisense oligonucleotide therapeutics.Biomater Res. 2022 Sep 30;26(1):49. doi: 10.1186/s40824-022-00292-4. Biomater Res. 2022. PMID: 36180936 Free PMC article. Review.
-
2'-O-(N-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity.Nucleic Acid Ther. 2022 Jun;32(3):221-233. doi: 10.1089/nat.2021.0086. Epub 2022 Mar 2. Nucleic Acid Ther. 2022. PMID: 35238623 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
